New hope for tough leukemia: experimental drug targets resistant cancers

NCT ID NCT06549790

Recruiting now Disease control Sponsor: Nerviano Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, NMS-03597812, in adults with acute myeloid leukemia that has come back or not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink or control the cancer. About 124 people will take part, including those with a specific gene change (TP53 mutation) that often makes the disease harder to treat.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Blood and Marrow Transplant Group of Georgia
RECRUITING

Atlanta, Georgia, 30342, United States
City of Hope - Duarte
RECRUITING

Duarte, California, 91010, United States
Gabrail Cancer Research Center
RECRUITING

Canton, Ohio, 44718, United States
Mayo Clinic Cancer Center (MCCC) - Rochester
WITHDRAWN

Rochester, Minnesota, 55905, United States
Medical Oncology Hematology Consultants
RECRUITING

Newark, Delaware, 19713, United States
Rocky Mountain Cancer Centers
RECRUITING

Aurora, Colorado, 80012, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.